Ventfort
/ Khavinson-tradition vascular bioregulator (KED-class variant)ALIAS · Ventfort · Vascular peptide bioregulator
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4. Ventfort is a Khavinson-tradition peptide bioregulator presented as a vascular-tissue extract or KED-class derivative depending on source. The molecule sits within the Saint Petersburg Institute of Bioregulation and Gerontology programme of low-molecular-weight 'cytogen' peptides; Western primary-literature replication is essentially absent.
Within the Khavinson tradition, ventfort is positioned as a vascular-endothelium peptide bioregulator producing tissue-specific effects on endothelial cell maturation and gene expression. The mechanistic claim invokes the broader 'peptide bioregulator' hypothesis articulated by Khavinson and collaborators, in which short peptides are proposed to modulate transcription via direct DNA interaction in a tissue-specific manner. This hypothesis has not been independently established outside the originating laboratory and the molecular pharmacology of ventfort specifically has not been characterised in indexed Western primary literature.
Tier 4. Discussion is confined largely to Russian-language reviews and chapters from the Khavinson group and immediate collaborators. No Phase 1 or later trials in indexed Western literature; no defined chemical structure published with sufficient detail for independent identity confirmation.
No formal Phase 1 human safety database in Western literature. Russian use is reported as well tolerated within the originating clinical tradition; this does not substitute for an independent safety database.
Regulatory status
- FDA status:
- Not FDA-approved
Russian-origin literature without independent Western replication is the central evidentiary issue. Ventfort is presented in the trade as a defined product but the published record does not include a peer-reviewed structural or pharmacological characterisation that vendor product can be checked against. The peptide-bioregulator transcriptional-modulation hypothesis itself remains a single-school claim.